Vitamin C Supplementation Shows Promise in Slowing Blood Disorders That Precede Leukemia

A phase 2 clinical trial investigating vitamin C's effects on precancerous blood disorders found that patients taking 1,000 mg daily experienced fewer adverse events and showed favorable changes in inflammation-related molecules compared to placebo controls. Exploratory analysis suggested improved survival rates after three years of follow-up in the vitamin C group, though this finding requires confirmation in a larger study. The results suggest vitamin C may influence biological pathways involved in abnormal blood cell growth in conditions that can progress to acute myeloid leukemia.

The study enrolled 109 patients with two related blood conditions—CCUS and MDS—that carry risk of progressing to acute myeloid leukemia. More than half of the participants showed vitamin C deficiency at baseline. The researchers tracked inflammation-signaling molecules called cytokines and found vitamin C supplementation altered these levels in ways associated with better clinical outcomes, suggesting the vitamin influences biological processes underlying abnormal blood cell development.

Laboratory research has identified TET2 as a key enzyme supporting normal gene regulation; mutations in this enzyme frequently appear in leukemia cases and confer growth advantages to abnormal cells. Vitamin C supports TET2 function in cellular models and animal research. The EVITA trial represents a shift toward testing affordable oral supplementation rather than intravenous administration, which achieves higher but less practical blood concentrations.